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Abstract
Non-bacterial thrombotic endocarditis or also called verrucous endocarditis or 
Libman-Sacks endocarditis or marantic endocarditis is a rare entity, still unknown 
physiopathology, which is characterized by the formation of sterile vegetations at 
the valvular structures. These vegetations of platelet aggregates and fibrin are sterile 
by definition, so for its definitive diagnosis, it is essential to rule out an infectious 
endocarditis. It is mainly diagnosed by echocardiography in patients with neoplasms 
or systemic autoimmune diseases. Its main complication is the formation of multi-
systemic embolisms, preferably at the brain level, so anticoagulation will be funda-
mental in the treatment and evolution of non-bacterial thrombotic endocarditis.
Keywords: Libman-Sacks endocarditis, marantic endocarditis,  
non-bacterial thrombotic endocarditis, non-infective endocarditis,  
verrucous endocarditis
1. Introduction
Non-bacterial thrombotic endocarditis (NBTE) is a rare entity in which a state of 
hypercoagulability predisposes to the formation of sterile vegetations in heart valves 
and secondary systemic embolisms, mainly in the central nervous system. In many 
occasions, the diagnosis is made postmortem, finding up to 0.2% of the autopsies of 
the general population [1]. The pathogenesis is unknown, being associated mainly 
with the existence of neoplastic processes and systemic autoimmune diseases (mainly 
in systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS)).
For the diagnosis it is necessary to demonstrate the presence of valvular vegeta-
tions by echocardiography, ruling out the existence of an underlying infection. 
There is no specific treatment, so it is recommended to control the predisposing 
disease and the initiation of anticoagulation to avoid the production of systemic 
embolisms [2].
2. Epidemiology and etiology
The NBTE is a rare pathology, whose diagnosis occurs generally in autopsies, 
being present in 0.9–1.2% of them, according to the series [3]. However, it is 
believed to be an underdiagnosed entity. It is described at any age, although it is 
more prevalent in patients between 40 and 80 years of age. Children tend to present 
milder clinical forms, with a lower number of systemic embolisms [4].
Infective Endocarditis
2
The neoplastic disease, generally advanced, is the main risk factor for the 
development of NBTE. If compared with the general population, this subgroup 
has a higher risk of presenting it (1.25 vs. 0.2%, respectively) according to a series 
of autopsies [5, 6]. The adenocarcinomas (i.e., colon, ovary, lung) are the most 
a. Malignancy
• Mucin-secreting and pancreatic adenocarcinoma
• Lung malignant neoplasm
• Ovary carcinoma
• Colon carcinoma
• Prostate carcinoma
• Cholangiocarcinoma
• Lymphoma
b. Systemic autoimmune diseases
• Systemic lupus erythematosus
• Antiphospholipid syndrome
• Systemic vasculitis
 ° Giant cell arteritis
 ° Behçet disease
 ° Takayasu’s arteritis
 ° Polyangiitis with granulomatosis
c. Hypercoagulability states
• Protein S and C deficiency
• Disseminated intravascular coagulation
• Thrombotic microangiopathy
 ° Thrombotic thrombocytopenic purpura
 ° Catastrophic antiphospholipid syndrome
d. Chronic inflammatory status
• Tuberculosis
• Uncontrolled HIV
• Chronic pyelonephritis
• Chronic osteomyelitis
e. Others
• Adenomyosis
• Hypereosinophilic syndrome
• Chronic alcoholism
• Chronic renal insufficiency
• Heart failure with valvulopathy
• Toxic oil syndrome
Table 1. 
Causes of NBTE.
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frequent tumors, observing a greater number of cases in the pancreatic and mucin 
secretors. Other pathologies that are associated are the SLE and the APS. In the 
SLE, different observational studies show a prevalence ranging between 6 and 11%, 
being more frequent among lupus patients with antiphospholipid antibodies [7]. 
Although exceptionally, NBTE can be a complication of systemic infections such 
as tuberculosis and HIV, and cases have been described in the context of uremia, 
adenomyosis, and even giant cell arteritis [8]. It should be said that in the cases 
mentioned of infectious etiology (i.e., tuberculosis, HIV), the development of 
NBTE is not determined directly by microorganisms, but by alterations in coagula-
tion induced by the underlying chronic inflammatory process (Table 1).
3. Pathogenesis
NBTE is a type of noninfectious endocarditis whose physiopathology continues 
to be unknown. It is characterized by the deposition of sterile platelet thrombi in 
the heart valves. In certain situations of hypercoagulability, endothelial damage 
occurs that favors the migration of mononuclear inflammatory cells and platelet 
deposition, being these responsible for the formation of fibrin thrombi and immune 
complexes (thrombi known as “white thrombus”). The term Libman-Sacks is used 
when you see a large thrombus or “wart” (verrucous endocarditis).
One of the main and differential characteristics of this entity is that the valvular 
vegetations must always be sterile (unlike infectious endocarditis (IE)). The mitral 
and aortic valves are the most frequently affected (rare right endocarditis), and it 
is common for NBTE to appear on healthy native valves, endocardium, or chordae 
tendineae.
Unlike IE, vegetations of the NBTE are more friable because they develop on a 
tissue with an important inflammatory reaction. This makes them more likely to 
produce systemic embolisms. They are located in the valvular coaptation lines and 
Figure 1. 
ETE-3D: Three-dimensional view of the aortic valve showing a rupture of the left coronary leaflet with 
images suggesting multiple vegetations of the valve in a 56-year-old man with Libman-Sacks endocarditis and 
SLE. ETE-Velos: Short axis view of the aortic valve showing a rupture of the left coronary leaflet with images 
suggesting thickening and multiple vegetations in the leaflets.
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are generally not accompanied by destruction of the valvular tissue. In terms of 
their size, they tend to be smaller and develop on a broad and irregular basis [9].
In NBTEs associated with malignancy, it is believed that macrophages interact 
with tumor cells, causing a migration of cytokines (tumor necrosis factor, interleu-
kin-1, etc.) that produces endothelial tissue damage and the formation of friable 
thrombi due to the deposition of platelets. On the other hand, the macrophage-
tumor cell interaction favors overactivation of the coagulation cascade, which in 
turn worsens the state of hypercoagulability that underlies the process. For this 
reason, NBTE tends to develop around areas of greater valve turbulence [3].
Libman-Sacks endocarditis is the most characteristic cardiac manifestation of 
SLE, with pericarditis being the most frequent cardiac manifestation [10]. It was first 
described in 1924, by Libman and Sacks at Mount Sinai Hospital in New York. From the 
macroscopic point of view, these deposits, usually located on the ventricular surface of 
the posterior leaflet of the mitral valve, are translated into vegetations with progressive 
growth or only thickening of the leaflets (Figure 1). The classic histopathological lesion 
consists of a deposit of fibrin and mononuclear cells. The immunofluorescence reveals 
immunoglobulin deposit and complement. Valvular involvement is usually silent and 
occurs in approximately half of patients with SLE, although in some cases valvular 
dysfunction can be the origin of heart failure. As in other NBTEs, the mitral and aortic 
valves are affected more frequently than those on the right side, with valvular insuf-
ficiency prevailing over the stenosis. The presence of lupus anticoagulant increases the 
risk of suffering thrombotic and embolic phenomena in these patients [11].
4. Clinical presentation
NBTE is characterized as an asymptomatic disease in early stages, whose most 
frequent initial manifestation is the presence of systemic embolisms. Although it 
can occur at any age, it is believed that young patients are less likely to suffer from 
embolic phenomena at a distance.
The clinic of valvular dysfunction (in the form of heart failure, syncope, etc.) usu-
ally appears in more advanced stages of the disease, and although it is recognizable by 
echocardiographic studies, they usually have little hemodynamic repercussion, except 
in advanced cases or the presence of large masses. The development of heart failure is 
present in less than half of patients with underlying valvular dysfunction.
4.1 Characteristics of embolisms
Given the rarity of this entity, the incidence of embolisms at the systemic level is 
not known. It is believed that it can appear from 14 to 91% of the NBTE. The embo-
lisms, some with hemorrhagic transformation, are more frequent in cases associated 
with malignancy [12]. In these patients, embolisms are evident in up to 50% of the 
cases, the most frequent clinical form being the central nervous system involvement.
Patients with NBTE usually debut in the form of multiple embolisms, especially 
distributed throughout the brain territory in the form of multiple infarcts (some-
times casual diagnosis after performing brain imaging tests). This contrasts with IE, 
where typically infarcts are usually focal and/or localized.
4.2 Signs and symptoms
Most patients are asymptomatic during the early stages of the disease. In fact, the 
appearance of fever, weight loss, and night sweats is uncommon, and its presence 
should guide us in the search for an underlying neoplastic process. On the other hand, 
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the association of arthritis, photosensitive skin lesions, and arterial and/or venous 
thromboses requires screening for systemic autoimmune diseases (SLE or APS).
The typical form of presentation (in more than half of the cases) derives from 
the symptoms and signs that occur as a result of the presence of systemic embo-
lisms. Although they can be produced in different organs (CNS, kidney, spleen, 
skin, etc. ), in 50% of cases, embolisms are observed at the pulmonary level, 
sometimes in the absence of valvular lesions in right cardiac cavities [13].
Sometimes the symptoms may be mild or nonspecific, such as hematuria, 
lumbar pain, and rash, in the context of renal, splenic, or cutaneous embolisms, 
respectively. However, the presence of coronary and CNS lesions is more specific 
and helps the diagnosis more early (chest pain, psychomotor agitation, delirium, 
stroke, etc.). The debut in the form of valvular insufficiency or decompensated 
heart failure is very infrequent [14] (Figure 2).
5. Diagnosis
The diagnosis of NBTE is a challenge for the clinician (which is why it is often 
diagnosed after carrying out necropsies) and not only due to the lack of specificity 
of the clinic but also because it occurs in advanced stages of the disease.
The diagnosis of NBTE is made through a high clinical suspicion after observing 
systemic manifestations derived from systemic embolisms and after performing comple-
mentary imaging tests (echocardiogram and transesophageal echocardiography mainly) 
that confirm the presence of valvular vegetations. However, the definitive diagnosis can 
be obtained after histologically demonstrating the presence of platelet thrombi at the 
level of the cardiac valves. It is a rare phenomenon, since valvular biopsies are not per-
formed routinely. For this, it is essential to rule out the presence of a systemic infection 
and to identify the underlying etiology (mainly autoimmune neoplasms and diseases).
It is necessary to make a correct differential diagnosis that includes IE, degener-
ative valvular disease, rheumatic valvular disease, and normal anatomic variants. 
Applying the modified Duke’s criteria can help establish the IE diagnosis [15].
Figure 2. 
ETT-IM: Four-chamber color view showing a jet of severe mitral regurgitation in a 48-year-old man with 
catastrophic antiphospholipid syndrome.
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Therefore, we should suspect an NBTE in those patients with active neoplasia, 
SLE or, APS who present coronary or CNS ischemia or, in the absence of said 
predisposing pathologies, in those cases in which we suspect an IE (without 
microbiological findings) that does not respond adequately directed empirical 
antibiotic treatment and that evolves torpidly with a greater number of systemic 
embolisms.
5.1 Laboratory and microbiology test
There are no specific analytical tests that suggest the presence of an 
NBTE. Depending on the causative disease, we can find analytical alterations that 
support or not a diagnosis. A complete blood test should be performed, including 
blood count, biochemistry, liver test, and coagulation panel. In some patients with 
NBTE, data of disseminated intravascular coagulation can be evidenced. In case 
of suspicion of autoimmune disease, a complete immunological study should be 
requested, mainly from SLE and APS (including antinuclear antibody, anti-double-
stranded DNA, and antiphospholipid antibodies). It will be necessary to carry out a 
screening of the most frequent types of neoplasms taking into account the sex, the 
comorbidities, and the age range of the patient.
Many authors suggest that before diagnosing an NBTE, it is essential to rule 
out an IE after carrying out different microbiological tests. In fact, at least three 
sets of blood cultures must be made before any suspicion of IE. Sometimes blood 
cultures in the presence of valvular vegetations can be persistently negative 
and do not rule out the presence of IE (called “culture-negative endocarditis”). 
For this reason, cultures of other biological fluids (urine, feces, etc.) should be 
performed, and serology and PCR should be performed on those less frequent 
or “atypical” microorganisms that can also cause IE (e.g., Brucella spp., Coxiella 
burnetii, Legionella, etc.) (Table 2).
5.2 Radiological image tests
The performance of radiological image tests will depend on the symptom-
atology that the patient presents, since they will provide information in those 
cases of complicated NBTE. In chest X-ray, we can observe data that suggest 
heart failure (cardiomegaly, pleural effusion, etc.). Cranial computed tomog-
raphy (CT) and magnetic resonance (MR) imaging are very useful for the 
diagnosis of cerebral embolisms, since if we suspect an NBTE, multiple infarcts 
will be observed, widely distributed, heterogeneous in size, and mainly isch-
emic. Cardiac MR or positron emission tomography may help in the differential 
diagnosis.
1. Previous antibiotic treatment
2. Technical problems with microbiological diagnosis
3. Acute renal failure or renal insufficiency
4. Ventricular or atrial septal defects, cardiac thrombi post-acute coronary disease, or cardiac pacemaker 
infection
5. Unusual microorganisms (Brucella spp., Coxiella burnetii, Bartonella spp., Legionella spp., Mycoplasma 
spp., Tropheryma whipplei, mycotic infections, and HACEK group infections—Haemophilus spp., 
Aggregatibacter spp., Cardiobacterium hominis, Eikenella corrodens, and Kingella species)
Table 2. 
Culture-negative endocarditis causes.
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5.3 Echocardiography
In those patients with suspected NBTE, a two-dimensional transthoracic echo-
cardiography (TTE) should be performed to demonstrate the presence of vegeta-
tions or valvular thickening (Figure 3). Vegetations in the NBTE usually appear 
in left valves, with the mitral valve most frequently affected (up to 75% of cases) 
followed by the aortic valve. Several valves can be affected simultaneously, although 
it is usually an uncommon finding (Figure 4).
Figure 3. 
ETE-2C: Mid-esophageal two-chamber view showing a 28-mm vegetation in the mitral valve.
Figure 4. 
ETE-2C: Mid-esophageal two-chamber color view. A vegetation in the mitral valve can be visualized. A severe 
mitral regurgitation jet is shown in this figure.
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However, TTE has several limitations. Small vegetations (below 5 mm) may go 
unnoticed, so if the clinical suspicion is still high, there is an indication to perform a 
transesophageal echocardiography (TEE), since it is more sensitive and specific than 
the TTE in detecting smaller vegetations. Do not forget that very small vegetations 
(<3 mm) cannot be detected by both types of echocardiogram, being able to obtain 
“false negatives.” If the clinical suspicion persists, echocardiographic study should be 
repeated after a prudential time. Although TTE is less sensitive and specific than TEE, 
it should always be performed not only to confirm the presence of endocarditis but 
also to evaluate other fundamental parameters such as function and cardiac volumes.
Although the echocardiogram is essential in the diagnosis of valvular vegeta-
tions, it will not be useful for the differential diagnosis of the type of endocarditis 
(thrombotic infection vs. aggregations of platelets and fibrin).
5.4 Histology
Although the definitive diagnosis is histological, most of the anatomopathologi-
cal tests of valvular vegetations are obtained from necropsies or after valve replace-
ment after the finding of a severe dysfunction or insufficiency, being very rare the 
biopsies of tendinous, valvular cords, or endocardial.
6. Treatment and management
There is no specific treatment for NBTE. The two basic pillars are systemic 
anticoagulation and targeted specific treatment of the associated disease (che-
motherapy, corticosteroids, etc.). In general, surgery by means of intervention, 
debridement, or valve replacement is usually not necessary and is rarely indicated.
6.1 Anticoagulation
Anticoagulant treatment is essential in the management of NBTE since it aims 
to prevent the production of systemic embolisms. In fact, unlike EI, these patients 
have an indication for anticoagulation for long periods of time or even indefinitely 
(unless absolutely contraindicated), regardless of whether embolic phenomena are 
observed or not. This fact is based on the fragility of the vegetations and the recur-
rent tendency to systemic embolization, especially in the absence of antithrombotic 
therapy. It should always be anticoagulated with a double objective: preventive and 
therapeutic. There are no published randomized clinical trials or prospective stud-
ies, so the recommendations are based on case series and retrospective studies and 
are supported by the American College of Chest Physician’s antithrombotic therapy 
for valvular heart disease guidelines [16].
Anticoagulation will be carried out by subcutaneous low molecular weight hepa-
rin or intravenous unfractionated heparin at anticoagulant doses. All the evidence 
published to date supports the use of this pharmacological family and does not 
recommend the use of warfarin, direct thrombin, nor factor Xa inhibitor (direct 
oral anticoagulants like apixaban, rivaroxaban, dabigatran, or edoxaban) especially 
in patients with active neoplastic disease since they seem to have less efficacy in the 
reduction of systemic embolisms. There is no data to support the use of the new 
anticoagulants. Recently the first case of cancer-associated non-bacterial thrombotic 
endocarditis in the era of direct oral anticoagulants was published where a patient with 
a previous history of thromboembolic disease developed a NBTE with vegetations and 
multiple cerebral embolisms in the context of a pancreatic adenocarcinoma despite 
being under treatment with rivaroxaban at optimal doses [17]. This case supports the 
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need to carry out more studies that help to elucidate the physiopathogenic mechanisms 
of the NBTE with the aim of achieving an optimal anticoagulant regimen.
The most frequent complications are life-threatening bleeding and thrombocy-
topenia. The development of any of these complications will force clinicians to raise 
the risk-benefit of their use and therefore to value discontinuing their use.
6.2 Surgery
In general, indications for valve replacement or vegetation excision are very lim-
ited in the NBTE. The main objective of surgery in the NBTE is to reduce or prevent 
the production of systemic embolisms. Because there are no prospective clinical 
trials, the same recommendations should be followed as in patients with IE [18].
However, unlike IE, we will try to preserve the valve as much as possible and 
focus all the objectives in controlling the state of hypercoagulability by treating 
predisposing disease.
When deciding whether a patient is going to benefit from surgery, it is essential 
to assess the risk-benefit individually. The surgical repair of heart valve is prefer-
able (it is less aggressive, has less mortality, and in general decreases the need for 
postoperative anticoagulation), with respect to valve replacement. The latter will 
be considered depending on the complications and the degree of destruction or 
valvular insufficiency. We must take into account the prognosis of life and morbid-
ity and mortality, especially in patients with advanced neoplastic diseases. Although 
there is little evidence, it is believed that anticoagulation should be maintained after 
surgery, especially in patients with systemic autoimmune diseases (mainly in APS).
6.3 Treatment for underlying disease
The treatment of neoplasia or systemic autoimmune disease is a fundamental 
pillar in the management of NBTE. It is very probable that at the time of diagnosis 
of the neoplasm, distant metastases are already observed, which will consider-
ably reduce the probability of therapeutic success. The same is not true in patients 
with SLE, where NBTE can be diagnosed at any time and whose presence does not 
correlate with the activity index. The treatment of patients with lupus valve disease 
includes prophylaxis of endocarditis, antiplatelet or anticoagulant treatment in 
selected cases, and valvular replacement when valvular involvement is severe; the 
role of corticosteroid treatment in the evolution of valvular disease is still undeter-
mined. Regarding the type of surgical intervention, there are controversies. Some 
authors suggest the superiority of mechanical prostheses in this type of condition 
over bioprostheses, including cryopreserved homografts, as these can contract 
lupus valvulitis on the new valve. However, other authors have advocated recon-
structive surgery to avoid the disadvantages of a mechanical prosthesis in young 
patients who usually require high doses of steroids and anticoagulant therapy [19].
It is unknown whether NBTE improves with antineoplastic therapy, and there-
fore it is believed that anticoagulation should be maintained independently of the 
response to treatment of the underlying disease.
7. Evolution and prognosis
7.1 Follow-up
The follow-up should be individualized depending on the characteristics and 
morbidities of each patient. It will be necessary to take into account possible 
Infective Endocarditis
10
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Carmen Busca-Arenzana, Angel Robles-Marhuenda*, Luis Ramos-Ruperto 
and Jorge Alvarez-Troncoso
Internal Medicine Department, La Paz University Hospital, Madrid, Spain
*Address all correspondence to: aroblesmarhuenda@gmail.com
complications of the disease or treatment: systemic embolization, bleeding, or 
thrombocytopenia. It will be necessary to periodically perform echocardiograms to 
monitor valve function, control the development of new vegetations (or check their 
resolution), as well as monitor the appearance of an IE concomitantly.
7.2 Prognosis
The prognosis of NBTE has not been correctly evaluated in prospective studies. 
In general, the prognosis of these patients is poor, although it will depend on the 
type of disease and the type or location of the complications, independently of the 
anticoagulant treatment.
8. Conclusions
• The NBTE is an entity characterized by the presence of vegetations of noninfec-
tious origin constituted by fibrin and platelet accumulations with high emboligenic 
potential.
• The most frequent etiologies are neoplasms (especially carcinoma of the pancreas) 
in an advanced or disseminated phase, without forgetting the systemic immune-
mediated processes such as lupus.
• Embolism and valvular dysfunction are the two most frequent complications 
found in NBTE. The incidence of systemic embolisms is around 50% in malignant 
NTBE, with neurological manifestations being the most common.
• The therapeutic attitude in these patients should be directed toward the con-
trol of the underlying disease and the hypercoagulable state or the treatment of 
the embolisms.
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